<DOC>
	<DOCNO>NCT00510939</DOCNO>
	<brief_summary>This one first study combination Zarnestra plus Velcade man . A primary objective study therefore assess safety tolerability multiple dos Zarnestra plus Velcade patient AML . New treatment patient untreatable intensive chemotherapy age de novo AML patient post-relapse AML urgently require since , present , many drug use second line therapy use first induction response rate much low . - The following evidence suggest Velcade plus Zarnestra attractive therapeutic combination : AML patient . - Affymetrix gene profile data show expression NFkB1 5 myeloid cell line cell line test 35 % 250 patient sample ( data generate collaboration Sergio Ferrari Pier Paolo Piccaluga unpublished result , Institute University Modena , Italy ) - Preclinical evidence show AML cell suspension culture prevent develop de novo drug resistance mediate drug resistance . In Part B additional patient AML treat characterize tolerability , biological effect , clinical efficacy combination Velcade plus Zarnestra . Patients treatment AML undergo regular bone marrow aspirate biopsy assess response treatment . This facilitate frequent assessment biological endpoint ( reduction expression phosphorylation IKKb kinase , downstream marker signal along apoptosis , survival , proliferation cellular size ploidy ) make attempt confirm desire biological activity achieve maximum tolerate dose .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Efficacy Tipifarnib Plus Bortezomib Treatment Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Provision write informed consent 2 . Male female age &gt; 18 year newly diagnose Acute Myeloid Leukemia ( AML ) , de novo secondary , unfit conventional chemotherapy 3 . Male female Acute Myeloid Leukemia first relapse ( &gt; 60 year ) 4. WHO performance status ³ 2 , or/and unwillingness receive conventional chemotherapy 5 . Negative pregnancy test evidence postmenopausal status female patient . 6 . RASGRP1/APTX gene expression ratio calculate screen &gt; 10 ( part B.2 ) 1 . Serum bilirubin 2 x &gt; Upper Limit Normal ( ULN ) 2 . Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &gt; 3.5 x ULN 3 . Serum creatinine ³ 2.5 x ULN 24hour creatinine clearance £ 60 mL/min ( measure calculate CockcroftGault ) 4 . Patients AML FAB M3 classification ( APL ) 5 . Patients history another primary malignancy within previous 1 year basal cell carcinoma carcinoma situ , patient remission 6 . Any clinically defined central nervous system AML . 7 . Participation investigational drug study within 30 day prior entry 8 . Evidence uncontrolled infection CNSHemorrhagic 9 . Patients documented case human immunodeficiency virus ( HIV ) 10 . Peripheral Neuropathy Neuropathic Pain grade &gt; = 2 11 . Has know suspect hypersensitivity intolerance boron , mannitol , heparin , indwell catheter use 12 . Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment , New York Heart Association ( NYHA ) Class III IV heart failure ( Attachment 7 , NYHA Classification Cardiac Disease ) , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis 13 . RASGRP1/APTX gene expression ratio calculate screen &lt; 10 ( part B.2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>NFkB activity leukemia</keyword>
	<keyword>expression NFkB</keyword>
</DOC>